Overview

Intravenous Ketamine Plus Neurocognitive Training for Depression

Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rebecca Price
University of Pittsburgh
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Ketamine